For over seven million American with PTSD, aid is coming from a surprising source: the drug commonly known as Ecstasy. As featured in O Magazine, when combined with psychotherapy, cutting-edge research is showing that MDMA is three times more effective than current treatments for PTSD. In fact, an FDA-approved clinical trial showed
that all twenty patients who took low-dose MDMA within the context of just two therapy sessions improved dramatically.1
A single MDMA-assisted therapy session could accomplish as much as six or more months of traditional therapy.
“I’ m impressed,” says Mark Wagner, a clinical psychologist at the Medical University of South Carolina who assessed patients in the FDA study. “ There are a couple of areas in medicine, like hip replacement, where one day you are bedridden, and the next you’re out playing tennis. Or with Lasik surgery, you’re blind, and then you can see. Nothing in psychology is like that. But this was dramatic.” 2
That’s why Harvard doctors are joining a chorus of experts studying MDMA-assisted psychotherapy as a promising new treatment for PTSD. The medicine improves mood while diminishing fear and anxiety, which allows the patient to reexamine and release the traumatic memory in a safe environment. The only thing stopping the millions of people with PTSD from getting treatment is the government. It’s time to unlock the medicine cabinet on MDMA.
The mission of the Med-X Campaign is to help millions of peope suffering from PTSD by promoting the use of medical MDMA. Our goal is to transform ecstasy from a recreational drug into a government-approved prescription medication to be used as a safe and effective tool for therapeutic treatment of mental health disorders.
Currently, our organizational goals are to:
- Provide information and public awareness of a cure for PTSD
- Work with healthcare professionals to develop safe treatments.
- Encourage policy-makers to make MDMA medicine
